Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis
Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Despite improvements in therapy, breast cancer still contributes to high mortality rates. Survival of these patients becomes progressively worse upon diagnosis with cancer-associated thrombosis (CAT).…
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Watch live to hear the latest current and emerging clinical data on the use of immunotherapy in patients with melanoma, hepatocellular carcinoma (HCC), and l…
China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.
Anticoagulants have long been fundamental in preventing and treating thromboembolic disorders, with a recent shift of focus towards direct oral anticoagulants, thanks to their ease…
In this discussion, Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, is joined by Sanam Loghavi, MD, The University of Texas MD…
Join us at our annual in-person conference to hear expert speakers on LGBTIQ+ cancer care and make amazing networking connections!
Trial of tucatinib and trastuzumab also showed benefits for HER2-mutated breast cancer: Thursday 24 October 2024, Barcelona, Spain: Drugs designed to target HER2-postive breast cancer…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.